BeataHolkovaMD

Assistant Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine

Join to view full profile

Are you Dr. Holkova?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 47 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1250 E Marshall St
Internal Medicine
Richmond, VA 23298
Phone+1 804-828-7999

Fax+1 804-828-5941

Summary

Dr. Beata Holkova, MD is a hematologist in Richmond, Virginia. She is currently licensed to practice medicine in Virginia and Michigan. She is affiliated with VCU Medical Center and is an Assistant Professor at Virginia Commonwealth University.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
University at BuffaloResidency, Internal Medicine, 2001 - 2004
Comenius UniversityClass of 1991

Certifications & Licensure

VA State Medical License 2008 - 2022
MI State Medical License 2004 - 2011

Clinical Trials

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma Start of enrollment: 2008 Jul 09
Completed
Phase 2
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start of enrollment: 2010 Apr 26
Completed
Phase 1
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome Start of enrollment: 2010 May 01
Completed
Phase 1
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Start of enrollment: 2012 Dec 19
Completed
Phase 1
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
Completed
Phase 2
Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma Start of enrollment: 2013 Jun 01
Completed
Phase 1, Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
Beata Holkova, Danielle Shafer, Victor Yazbeck, Sandeep S. Dave, Prithviraj Bose
Leukemia & Lymphoma. 2021-04-16
26 citations
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design.
Ajay K. Nooka, Katja Weisel, Niels W.C.J. van de Donk, David Routledge, Paula Rodriguez Otero
Future Oncology. 2021-03-08
1 citations
Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occurandand proceed through multiple mechanisms.
Tri Nguyen, Rebecca Parker, Elisa Hawkins, Beata Holkova, Victor Yazbeck
Oncotarget. 2019-09-03

Professional Memberships

American Society of Clinical Oncology - ASCO
Member